Ultimately, the landscape of ALK inhibitor resistance mechanisms in NB will only become clear following the completion of current clinical trials, but is likely to involve both on- and off-target mechanisms as observed in NSCLC. Here, ALK is linked to non-small cell lung carcinoma.